OPDIVO 600 mg solution for injection
*Company:
Bristol-Myers Squibb Pharma EEIGStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 29 October 2025
File name
i.e-smpc-opdivo-sc-clean (09Oct25).pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
09 Oct 2025: For the Study CA20976K an additional RFS descriptive analysis (minimum follow-up 26.9 months) has been included.
Updated on 22 October 2025
File name
i.e-smpc-opdivo-clean (09Oct25).pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
09 October 2025: For the Study CA20976K an additional RFS descriptive analysis (minimum follow-up 26.9 months) has been included in section 5.1 of the SmPC
File name
1506-GB-2200414_BMS Opdivo Alert Card.pdf
Reasons for updating
- Add New Doc
Updated on 22 August 2025
File name
i.e-pil - opdivo-sc - clean (26May25).pdf
Reasons for updating
- New PIL for new product
Updated on 22 August 2025
File name
i.e-smpc-opdivo-sc - clean (26May25).pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Bristol-Myers Squibb Pharma EEIG
Address:
Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, IrelandMedical Information E-mail:
medical.information@bms.comTelephone:
+353 1 483 3625Medical Information Direct Line:
Freephone 1 800 749 749Stock Availability:
bmscustomer-service.chester@bms.com